All In MedTech

Device Trial Radar · NCT06991270

OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma

A Pilot Study of the OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Oct 8, 2025

Primary completion

Dec 1, 2026

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Sight Sciences, Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 27, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).

Conditions

  • Primary Open Angle Glaucoma

Interventions

  • OMNI 3.0 Surgical SystemDevice

    Canaloplasty and trabeculotomy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Panama Eye Center

    Panama City, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.